Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
NaviFUS Corporation
NaviFUS Corporation
Waikato Hospital
University Hospital, Caen
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Reveal Pharmaceuticals Inc.
University Hospital, Lille
Centre Hospitalier Universitaire de Nīmes
UNC Lineberger Comprehensive Cancer Center
Alpha Biopharma (Jiangsu) Co., Ltd.
Institut National de la Santé Et de la Recherche Médicale, France
Washington University School of Medicine
National Institutes of Health Clinical Center (CC)
Orphelia Pharma
PharmaMar
Hackensack Meridian Health
Alpheus Medical, Inc.
Azienda USL Reggio Emilia - IRCCS
Engeneic Pty Limited
Thomas Jefferson University
Children's Oncology Group
Dana-Farber Cancer Institute
Inova Health Care Services
Cedars-Sinai Medical Center
BPGbio
Centre Georges Francois Leclerc
BeiGene
University of Michigan Rogel Cancer Center
Taproot Health
Blueprint Medicines Corporation
St. Jude Children's Research Hospital
Emory University
Wake Forest University Health Sciences
University of Colorado, Denver
The Hong Kong Polytechnic University
St. Jude Children's Research Hospital
Martin-Luther-Universität Halle-Wittenberg
Basilea Pharmaceutica
IntuiTap Medical, Inc
St. Jude Children's Research Hospital
Columbia University
Cedars-Sinai Medical Center
Bayer
Seattle Children's Hospital
National Cancer Institute (NCI)
University of Texas Southwestern Medical Center
University of Alabama at Birmingham
Celgene
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc.